Pacific Biosciences Of California (PACB) Current Assets (2010 - 2026)

Pacific Biosciences Of California's Current Assets history runs 17 years deep, the most recent figure standing at $369.5 million for Q1 2026.

• On a quarterly basis, Current Assets fell 16.95% year-over-year to $369.5 million in Q1 2026; TTM through Mar 2026 was $369.5 million, a 16.95% decrease from a year earlier, with the FY2025 full-year figure at $375.1 million, down 24.34% from the prior year.
• Current Assets declined to $369.5 million in Q1 2026 per PACB's latest filing, from $375.1 million in the prior quarter.
• Across five years, Current Assets topped out at $1.0 billion in Q1 2022 and bottomed at $369.5 million in Q1 2026.
• The 5-year median for Current Assets is $677.0 million (2024), against an average of $687.6 million.
• Across the five-year window, Current Assets slipped 3.46% in 2023 and slumped 34.28% in 2025, its largest moves.
• Year by year, Current Assets stood at $852.1 million in 2022, then fell by 12.91% to $742.0 million in 2023, then sank by 33.2% to $495.7 million in 2024, then slipped by 24.34% to $375.1 million in 2025, then declined by 1.48% to $369.5 million in 2026.
• Per Business Quant, the three latest PACB Current Assets figures stand at $369.5 million (Q1 2026), $375.1 million (Q4 2025), and $394.2 million (Q3 2025).